Construction of a proteolysis-resistant peptide sequence of the food recombinant protein GDF-11 and plasmid synthesis for its expression in E. coli

Authors: Valieva Sh. S., Tikhonov S. L., Tikhonova N. V., Timofeeva M. S., Shikhalev S. V.

Source: Vestnik MGTU, Vol 28, Iss 2, Pp 143-150 (2025)

Subject Terms: proteolysis, гепатотоксичность, пептидная последовательность, General Works, peptide sequence, hepatoxicity, белок, allergenicity, cytotoxicity, аллергенность, цитотоксичность, protein, протеолиз

Access URL: https://doaj.org/article/893d7f04811f4ec7b77532f235b49dbf

Преодоление гепатотоксичности метотрексата: роль тритерпеноидов

Source: Клиническая онкогематология, Vol 6, Iss 1 (2025)

Subject Terms: гепатотоксичность, химиотерапия, метотрексат, тритерпеноиды, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, онкогематологические заболевания, RC254-282

Access URL: https://doaj.org/article/f83be0c1cdb44a77aa1c4d0f29526ffd

КЛИНИЧЕСКИЙ СЛУЧАЙ ЛЕКАРСТВЕННОГО ПОРАЖЕНИЯ ПЕЧЕНИ

Source: University Therapeutic Journal, Vol 7, Iss 1 (2025)

Subject Terms: идиосинкразия, лекарственная гепатотоксичность, Medicine, лекарственное поражение печени, биологически активные добавки

Access URL: https://doaj.org/article/8c38fd3a62ba49cdb234a9336111a3ab

Роль полиморфных вариантов генов цитохромов Р450, а также генов GSTP1 и MDR1 в развитии токсических осложнений при проведении программной противоопухолевой лекарственной терапии у пациентов с классической лимфомой Ходжкина

Source: Клиническая онкогематология, Vol 17, Iss 2 (2024)

Subject Terms: гепатотоксичность, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, полиморфизм генов, кардиотоксичность, гены MDR1, цитохромы Р450, RC254-282, классическая лимфома Ходжкина, 3. Good health

Access URL: https://doaj.org/article/e2c1c5644cbb43d1ba268088e3332654

С ЛИМФОПРОЛИФЕРАТИВНЫМИ ЗАБОЛЕВАНИЯМИ НА ЭТАПАХ ПОЛИХИМИОТЕРАПИИ

Source: Высшая школа: научные исследования.

Subject Terms: полихимиотерапиия, лимфомы, гепатотоксичность, гипераммониемия, энцефалопатия

Diagnosis and Prognostic Assessment of Drug-Induced Liver Injury: What Are the Outpatient Options? (Review) ; Диагностика и прогностическая оценка лекарственно-индуцированного поражения печени: каковы возможности в амбулаторных условиях? (Обзор)

Authors: E. V. Gantsgorn, A. V. Bozhko, S. V. Yarchenko, Е. В. Ганцгорн, А. В. Божко, С. В. Ярченко

Contributors: The study was performed without external funding, Работа выполнена без спонсорской поддержки

Source: Safety and Risk of Pharmacotherapy; Том 13, № 1 (2025); 58-69 ; Безопасность и риск фармакотерапии; Том 13, № 1 (2025); 58-69 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2025-13-1

Subject Terms: лекарственный мониторинг, hepatotoxity, outpatient treatment, early diagnosis, adverse drug reaction, CIOMS/RUCAM scale, safety of pharmacotherapy, risk factors, drug monitoring, гепатотоксичность, амбулаторное лечение, ранняя диагностика, нежелательная реакция, шкала CIOMS/RUCAM, безопасность фармакотерапии, факторы риска

File Description: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/447/1356; https://www.risksafety.ru/jour/article/downloadSuppFile/447/529; https://www.risksafety.ru/jour/article/downloadSuppFile/447/608; Коренская ЕГ, Парамонова ОВ. Лекарственные поражения печени — одна из важных проблем у коморбидного пациента. Consilium Medicum. 2019;21(8):78–83. https://doi.org/10.26442/20751753.2019.8.190355; European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–61. https://doi.org/10.1016/j.jhep.2019.02.014; Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516–37. https://doi.org/10.1016/j.jhep.2023.03.017; Маев ИВ, Полунина ТЕ. Лекарственные повреждения печени: диагноз исключения. Терапевтический архив. 2023;95(8):611–20. https://doi.org/10.26442/00403660.2023.08.202329; Aithal GP, Kulkarni AV. Drug-induced liver injury. Medicine. 2023;51(5):342–6. https://doi.org/10.1016/j.mpmed.2023.02.006; Hoofnagle JH, Björnsson ES. Drug-induced li­ver injury — types and phenotypes. N Engl J Med. 2019;381(3):264–73. https://doi.org/.1056/NEJMra1816149; Nedashkivskyi SM. Drug-induced liver damage: Principles of diagnosis, pathological changes and approaches to treatment. Emergency Medicine. 2019;97(2):63–70. https://doi.org/10.22141/2224-0586.2.97.2019.161644; Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: Mechanistic and clinical challenges. Int J Mol Sci. 2021;22(6):2954. https://doi.org/10.3390/ijms22062954; Kwon J, Kim S, Yoo H, Lee E. Nimesulide-induced hepatotoxicity: A systematic review and meta-analysis. PLoS One. 2019;14(1):e0209264. https://doi.org/10.1371/journal.pone.0209264; Ниёзова ШХ. ­Гепатотоксический ­синдром на фоне полихимиотерапии солидных опухолей и современные возможности его коррекции (обзор литературы). Вестник науки и образования. 2019;(17):73–6. https://doi.org/10.24411/2312-8089-2019-11704; Мехтиев СН, Зиновьева СН, Мехтиева ОА. Лекарственные поражения печени при многокомпонентной терапии коморбидных состояний. Экспериментальная и клиническая гастроэнтерология. 2015;6(118):71–7. EDN: UHYNMN; Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroentero­logy. 2013;144(7):1419–25. https://doi.org/10.1053/j.gastro.2013.02.006; Lancaster EM, Hiatt JR, Zarrinpar A. Acetaminophen hepatotoxicity: An updated review. Arch Toxicol. 2015;89(2):193–9. https://doi.org/10.1007/s00204-014-1432-2; Байкова ИЕ, Никитин ИГ. Лекарственное поражение печени. РМЖ. 2009;1:4–10.; Безвуляк ЕИ, Башарин ВА, Епифанцев АВ, Куценко ВП, Селиверстов ПВ. Возможности профилактики токсического лекарственно-индуцированного поражения печени при химиотерапии онкологических заболеваний. Медицинский совет. 2020;(5):42–9. https://doi.org/10.21518/2079-701X-2020-5-42-49; Aithal GP, Nicoletti P, Björnsson E. HLAA*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and seve­ral other unrelated compounds. Hepatology. 2015;65( 1):325–26. https://doi.org/10.1002/hep.28203; Sandhu N, Navarro V. Drug-induced liver injury in GI practice. Hepatol Commun. 2020;4(5):631–45. https://doi.org/10.1002/hep4.1503; Лазебник ЛБ, Голованова ЕВ, Хлынова ОВ, Алексеенко СА, Арямкина ОЛ, Бакулин ИГ и др. Лекарственные поражения печени (ЛИПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29–54. https://doi.org/10.31146/1682-8658-ecg-174-2-29-54; Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41. https://doi.org/10.1007/s12072-017-9793-2; Yang WN, Pang LL, Zhou JY, Qiu YW, Miao L, Wang SY, et al. Single-nucleotide polymorphisms of HLA and Polygonum multiflorum-induced liver injury in the Han Chinese population. World J Gastroenterol. 2020;26(12):1329–39. https://doi.org/10.3748/wjg.v26.i12.1329; Яковенко ЭП, Агафонова НА, Яковенко АВ, Иванов АН, Ковтун АВ. Патогенетический подход к выбору гепатопротекторов в терапии лекарственно-индуцированных поражений печени. Лечебное дело. 2017;(2):34–40. EDN: YZKMZN; Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci. 2015;17(1):14. https://doi.org/10.3390/ijms17010014; Буеверов АО. Лекарственные поражения печени: проблема, не теряющая актуальности. Доктор.Ру. 2016;2(119):57–64.; Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case characterization, clinical features and risk factors in drug-induced liver injury. Int Mol Sci. 2016;17(5):714. https://doi.org/10.3390/ijms17050714; Суханов ДС, Тимофеев ЕВ, Алексеева ЮС, Азовцев ДЮ. Лекарственные поражения печени при туберкулезе. Механизмы развития и методы диагностики. Juvenis Scientia. 2023;1(9):24–42. https://doi.org/10.32415/jscientia_2023_9_1_24-42; Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I, González-Jimenez A et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced li­ver injury. Gastroenterology. 2014;147(1):109–118.e5. https://doi.org/10.1053/j.gastro.2014.03.050; Губергриц НБ, Беляева НВ, Клочков АЮ. Лекарственное поражение печени: от патогенеза к лечению. Вестник клуба панкреатологов. 2020;46(1):72–80. EDN: ­HUVKED; Pessayre D, Larrey D. Drug-induced liver injury. In: Rodés J, Benhamou J–P, Blei A, Reichen J, Rizzetto M, eds. Textbook of hepatology: From basic science to clinical practice. Blackwell Publishing; 2007. P. 1211–77. https://doi.org/10.1002/9780470691861.ch14a; Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. https://doi.org/10.1038/clpt.2011.58; Ганцгорн ЕВ, Арчакова МА, Манвелян РМ, Маллеев ИМ, Антонян БГ, Дзангиев ИИ и др. Клинический случай карбамазепин-индуцированного гепатита. Экспериментальная и клиническая фармакология. 2024;87(1):21–4. https://doi.org/10.30906/0869-2092-2024-87-01-21-24; Мазеркина ИА. Идиосинкратическая лекарственная гепатотоксичность — от патогенеза к снижению риска. Безопасность и риск фармакотерапии. 2023;11(2):204–14. https://doi.org/10.30895/2312-7821-2023-11-2-204-214; https://www.risksafety.ru/jour/article/view/447

Availability: https://www.risksafety.ru/jour/article/view/447
https://doi.org/10.30895/2312-7821-2025-447

ALCOHOLIC LIVER DISEASE: ISSUES OF ETIOLOGY AND THE IMPACT OF RISK FACTORS (LITERATURE REVIEW)

Authors: Daria A. Stepanenko, Tatyana V. Goma, Natalia M. Kozlova

Source: Байкальский медицинский журнал, Vol 2, Iss 2, Pp 20-29 (2023)

Subject Terms: алкогольная болезнь печени, хроническая алкогольная интоксикация, факторы риска, этанол, модели употребления алкоголя, гепатотоксичность, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.bmjour.ru/jour/article/view/65; https://doaj.org/toc/2949-0715

Access URL: https://doaj.org/article/03fe6b2ee820457088e844cda44268e0

Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19 ; Анализ потребления препаратов с высоким риском развития лекарственного поражения печени при COVID-19

Authors: V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva, В. И. Петров, А. Ю. Рязанова, Н. С. Токарева

Contributors: The study was performed without external funding., Работа выполнена без спонсорской поддержки.

Source: Safety and Risk of Pharmacotherapy; Том 12, № 3 (2024); 268-284 ; Безопасность и риск фармакотерапии; Том 12, № 3 (2024); 268-284 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2024-12-3

Subject Terms: АТС/DDD-анализ, drug-induced liver injury, COVID-19, alanine transaminase, hepatotoxicity, adverse drug reactions, antimicrobials, NSAIDs, omeprazole, favipiravir, remdesivir, ATC/DDD analysis, лекарственные поражения печени, аланиновая трансаминаза, гепатотоксичность, нежелательные реакции, антибактериальные препараты, нестероидные противовоспалительные средства, омепразол, фавипиравир, ремдесивир

File Description: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/396/1221; https://www.risksafety.ru/jour/article/view/396/1047; https://www.risksafety.ru/jour/article/view/396/1049; https://www.risksafety.ru/jour/article/view/396/1053; https://www.risksafety.ru/jour/article/view/396/1056; https://www.risksafety.ru/jour/article/view/396/1064; https://www.risksafety.ru/jour/article/view/396/1061; https://www.risksafety.ru/jour/article/view/396/1070; https://www.risksafety.ru/jour/article/view/396/1071; https://www.risksafety.ru/jour/article/view/396/1086; https://www.risksafety.ru/jour/article/view/396/1090; https://www.risksafety.ru/jour/article/downloadSuppFile/396/475; https://www.risksafety.ru/jour/article/downloadSuppFile/396/481; https://www.risksafety.ru/jour/article/downloadSuppFile/396/483; Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020;40(6):1321–6. https://doi.org/10.1111/liv.14449; Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561–6. https://doi.org/10.1016/j.cgh.2020.04.002; Yadav DK, Singh A, Zhang Q, Bai X, Zhang W, Yadav RK, et al. Involvement of liver in COVID-19: systematic review and meta-analysis. Gut. 2021;70(4):807–9. https://doi.org/10.1136/gutjnl-2020-322072; Pazgan-Simon M, Serafińska S, Kukla M, Kucharska M, Zuwała-Jagiełło J, Buczyńska I, et al. Liver injury in patients with COVID-19 without underlying liver disease. J Clin Med. 2022;11(2):308. https://doi.org/10.3390/jcm11020308; Olry A, Meunier L, Délire B, Larrey D, Horsmans Y, Le Louët H. Drug-induced liver injury and COVID-19 infection: the rules remain the same. Drug Saf. 2020;43(7):615–17. https://doi.org/10.1007/s40264-020-00954-z; Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, et al. Drug-induced liver injury in COVID-19 patients: a systematic review. Front Med (Lausanne). 2021;8:731436. https://doi.org/10.3389/fmed.2021.731436; Ивашкин ВТ, Барановский АЮ, Райхельсон КЛ, Пальгова ЛК, Маевская МВ, Кондрашина ЭА и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):101–31. https://doi.org/10.22416/1382-4376-2019-29-1-101-131; Цветов ВМ, Бурашникова ИС, Сычев ДА, Поддубная ИВ. Возможность и перспективы применения препаратов из группы цитостатиков у пациентов с COVID-19 на примере циклофосфамида. Фарматека. 2021;28(1):10–3. https://doi.org/10.18565/pharmateca.2021.1.10-13; Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327–34. https://doi.org/10.1007/s00204-015-1456-2; Буеверов АО, Богомолов ПО, Буеверова ЕЛ. Гепатотоксичность антибактериальных препаратов в терапевтической практике. Клиническая микробиология и антимикробная химиотерапия. 2015;17(3):207–16. EDN: UHPUXJ; deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, et al. Amoxicillin-clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406–16. https://doi.org/10.1007/s10620-016-4121-6; Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond). 2016;16(Suppl. 6):s104-s109. https://doi.org/10.7861/clinmedicine.16-6-s104; Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99. https://doi.org/10.1056/NEJMoa2001282; Fontana RJ, Hayashi P, Bonkovsky HL, Kleiner DE, Kochhar S, Gu J, Ghabril M. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci. 2013;58(6):1766–75. https://doi.org/10.1007/s10620-012-2553-1; Tsuzuki S, Hayakawa K, Dоi Y, Shinozaki T, Uemura Y, Matsunaga N, et al. Effectiveness of favipiravir on nonsevere, early-stage COVID-19 in Japan: a large observational study using the COVID-19 Registry Japan. Infect Dis Ther. 2022;11(3):1075–87. https://doi.org/10.1007/s40121-022-00617-9; Руженцова ТА, Чухляев ПВ, Хавкина ДА, Гарбузов АА, Плоскирева АА, Осешнюк РА и др. Эффективность и безопасность применения фавипиравира в комплексной терапии COVID-19 легкого и среднетяжелого течения. Инфекционные болезни: новости, мнения, обучение. 2020;9(4):26–38. https://doi.org/10.33029/2305-3496-2020-9-4-26-38; Bjork JA, Wallace KB. Remdesivir; molecular and functional measures of mitochondrial safety. Toxicol Appl Pharmacol. 2021;433:115783. https://doi.org/10.1016/j.taap.2021.115783; Петров ВИ, Рязанова АЮ, Привальцева НС, Некрасов ДА. Опыт применения ремдесивира для лечения новой коронавирусной инфекции. Безопасность и риск фармакотерапии. 2022;10(4):365–80. https://doi.org/10.30895/2312-7821-2022-10-4-365-380; Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(5):849–58. https://doi.org/10.1093/rheumatology/key361; Serviddio G, Villani R, Stallone G, Scioscia G, Foschino-Barbaro MP, Lacedonia D. Tocilizumab and liver injury in patients with COVID-19. Therap Adv Gastroenterol. 2020;13:1756284820959183. https://doi.org/10.1177/1756284820959183; Ortiz GX, Lenhart G, Becker MW, Schwambach KH, Tovo CV, Blatt CR. Drug-induced liver injury and COVID-19: a review for clinical practice. World J Hepatol. 2021;13(9):1143–53. https://doi.org/10.4254/wjh.v13.i9.1143; Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020;40(8):843–56. https://doi.org/10.1002/phar.2438; Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol. 2018;2018:5253623. https://doi.org/10.1155/2018/5253623; Schrör K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9(3):195–204. https://doi.org/10.2165/00148581-200709030-00008; Dart RC, Erdman AR, Olson KR, Christianson G, Manoguerra AS, Chyka PA, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2006;44(1):1–18. https://doi.org/10.1080/15563650500394571; Park BK, Dear JW, Antoine DJ. Paracetamol (acetaminophen) poisoning. BMJ Clin Evid. 2015;2015:2101. PMID: 26479248; Tsuda T, Tada H, Tanaka Y, Nishida N, Yoshida T, Sawada T, et al. Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. J Med Case Rep. 2018;12(1):95. https://doi.org/10.1186/s13256-018-1629-8; Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6(3):228–36. https://doi.org/10.2174/157016108784912019; Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15(8):921–4. https://doi.org/10.1097/00042737-200308000-00014; https://www.risksafety.ru/jour/article/view/396

Availability: https://www.risksafety.ru/jour/article/view/396
https://doi.org/10.30895/2312-7821-2024-396

Comprehensive assessment of subchronic low-dose exposure to doxorubicin in the Wistar rat model ; Комплексная оценка субхронического низкодозового воздействия доксорубицина на модели крыс линии Wistar

Authors: M. A. Asanov, A. O. Poddubnyak, R. A. Muhamadiyarov, A. V. Sinitskaya, M. V. Khutornaya, M. Yu. Sinitsky, М. А. Асанов, А. О. Поддубняк, Р. А. Мухамадияров, А. В. Синицкая, М. В. Хуторная, М. Ю. Синицкий

Contributors: The study was carried out with the support of a comprehensive program of fundamental scientific research of the SB RAS within the framework of the fundamental theme of the Research Institute of Complex Problems of Cardiovascular Diseases No. 0419-2022-0001., Исследование выполнено при поддержке комплексной программы фундаментальных научных исследований СО РАН в рамках фундаментальной темы НИИ КПССЗ № 0419-2022-0001 «Молекулярные, клеточные и биомеханические механизмы патогенеза сердечно-сосудистых заболеваний в разработке новых методов лечения заболеваний сердечно-сосудистой системы на основе персонифицированной фармакотерапии, внедрения малоинвазивных медицинских изделий, биоматериалов и тканеинженерных имплантатов».

Source: Siberian Journal of Clinical and Experimental Medicine; Том 39, № 4 (2024); 171-179 ; Сибирский журнал клинической и экспериментальной медицины; Том 39, № 4 (2024); 171-179 ; 2713-265X ; 2713-2927

Subject Terms: микроядро, hepatotoxicity, genotoxicity, doxorubicin, electron microscopy, micronucleus, гепатотоксичность, генотоксичность, доксорубицин, электронная микроскопия

File Description: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/2254/1033; Argun M., Üzüm K., Sönmez M.F., Özyurt A., Derya K., Çilenk K.T. et al. Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats. Anatol. J. Cardiol. 2016;16(4):234. DOI:10.5152/akd.2015.6185.; Guo R., Hua Y., Ren J., Bornfeldt K.E., Nair S. Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity. Cell Death Dis. 2018;9(6):692. DOI:10.1038/s41419-018-0727-2.; Anghel N., Herman H., Balta C., Rosu M., Stan M.S., Nita D. et al. Acute cardiotoxicity induced by doxorubicin in right ventricle is associated with increase of oxidative stress and apoptosis in rats. Histol. Histopathol. 2018;33(4):365. DOI:10.14670/hh-11-932.; Yu Q., Li Q., Na R., Li X., Liu B., Meng L. et al. Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy. Mol. Cell Biochem. 2014;387(1–2):279–285. DOI:10.1007/s11010-013-1894-1.; Hajra S., Patra A.R., Basu A., Bhattacharya S. Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: Effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation. Biomed. Pharmacother. 2018;101:228–243. DOI:10.1016/j.biopha.2018.02.088.; Jain A.K., Pandey A.K. In vivo micronucleus assay in mouse bone marrow methods. Mol. Biol. 2019;2031:135–146. DOI:10.1007/978-1-4939-9646-9_7.; Christidi E., Brunham L.R. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339. DOI:10.1038/s41419-021-03614-x.; Boriollo M.F.G., Alves V.E., Silva T.A., Silva J.J., Barros G.B.S. Dias C.T.S. et al. Decrease of the DXR-induced genotoxicity and nongenotoxic effects of Theobroma cacao revealed by micronucleus assay. Braz. J. Biol. 2021;81(2):268–277. DOI:10.1590/1519-6984.223687.; Mukhamadiyarov R.A., Bogdanov L.A., Glushkova T.V., Shishkova D.K., Kostyunin A.E., Koshelev V.A. et al. EMbedding and backscattered scanning electron microscopy: a detailed protocol for the whole-specimen, high-resolution analysis of cardiovascular tissues. Front. Cardiovasc. Med. 2021;8:739549. DOI:10.3389/fcvm.2021.739549.; Robert J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc. Toxicol. 2007;7:135–139. DOI:10.1007/s12012-007-0022-4.; Kalender Y., Yel M., Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology. 2005;209(1):39–45. DOI:10.1016/j.tox.2004.12.003.; Ivanová M., Dovinová I., Okruhlicová L., Tribulová N., Simončíková P., Barteková M. et al. Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats. Acta Pharmacol. Sin. 2012; 33(4):459–469. DOI:10.1038/aps.2011.194.; Chen P.Y., Hou C.W., Shibu M.A., Day C.H., Pai P., Liu Z.R. et al. Protective effect of Co-enzyme Q10 on doxorubicin-induced cardiomyopathy of rat hearts. Environ. Toxicol. 2017;32(2):679–689. DOI:10.1002/tox.22270.; Henderson K.A., Borders R.B., Ross J.B., Abdulalil A., Gibbs S., Skowronek A.J. et al. Integration of cardiac energetics, function and histology from isolated rat hearts perfused with doxorubicin and doxorubicin-ol; a model for use in drug safety evaluations. J. Pharmacol. Toxicol. Methods. 2018;94(2):54–63. DOI:10.1016/j.vascn.2018.08.004.; Подъячева Е.Ю., Шмакова Т.В., Андреева Д.Д., Торопов Р.И., Чебуркин Ю.В., Данильчук М.С. и др. Профиль молекулярных маркеров фиброза у крыс при воздействии различных доз доксорубицина. Журнал эволюционной биохимии и физиологии. 2023;59(2):121– 130. DOI:10.31857/S0044452923020043.; Liao H.E., Shibu M.A., Kuo W.W., Pai P.Y., Ho T.J., Kuo C.H. et al. Deep sea minerals prolong life span of streptozotocin-induced diabetic rats by compensatory augmentation of the IGF-I-survival signaling and inhibition of apoptosis. Environ. Toxicol. 2016;31(7):769–781. DOI:10.1002/tox.22086.; Nakashima M., Nakamura K., Nishihara T., Ichikawa K., Nakayama R., Takaya Y. et al. Association between cardiovascular disease and liver disease, from a clinically pragmatic perspective as a cardiologist. Nutrients. 202315(3):748. DOI:10.3390/nu15030748.; Asanov M.A., Shishkova D.K., Poddubnyak A.O., Sinicky M.Yu., Sinickaya A.V., Khutornaya M.V., et al. Dose-response assessment of mitomycin C genotoxic effect on ApoE knockout mice. J. Evol. Biochem. Physiol. 2023;59(5):1693–1699. DOI:10.1134/S0022093023050198.; Yang F., Teves S.S., Kemp C.J., Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta. 2014;1845:84–89. DOI:10.1016/j.bbcan.2013.12.002.; Ефимов В.А., Федюнин С.В. Кросс-сшитые нуклеиновые кислоты: получение, структура и биологическая роль. Успехи биологической химии. 2010;50:259–302. Efimov V.A., Fediunin S.V. Cross-linked nucleic acids: production, structure and biological role Uspekhi biologicheskoi khimii. 2010;50:259–302. (In Russ.). DOI:10.1073/pnas.1821022116.; Rymer J.A., Rao S.V. Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. Coron. Artery Dis. 2018;29(2):161–167. DOI:10.1097/MCA.0000000000000598.; https://www.sibjcem.ru/jour/article/view/2254

Availability: https://www.sibjcem.ru/jour/article/view/2254
https://doi.org/10.29001/2073-8552-2024-39-4-171-179

Safety profile of antituberculosis drugs ; PROFILUL DE SIGURANȚĂ AL MEDICAMENTELOR ANTITUBERCULOASE ; Профиль безопасности противотуберкулезных препаратов

Authors: ȚURCAN, Lucia, PODGURSCHI, Lilia, RAKOVSKAIA, Tatiana, SAITOV, Artur

Source: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 77 No. 3 (2023): Medical Sciences; 221-227 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 77 Nr. 3 (2023): Ştiinţe medicale; 221-227 ; Вестник Академии Наук Молдовы. Медицина; Том 77 № 3 (2023): Медицина; 221-227 ; 1857-0011

Subject Terms: противотуберкулезные препараты, побочные эффекты, гепатотоксичность, нейротоксичность, изониазид, рифампицин, линезолид, preparate antituberculoase, reacții adverse medicamentoase, epatotoxicitate, neurotoxicitate, isoniazida, rifampicina, linezolid, antituberculosis drugs, side effects, hepatotoxicity, neurotoxicity, isoniazid, rifampicin

File Description: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3600/3599; https://bulmed.md/bulmed/article/view/3600

Availability: https://bulmed.md/bulmed/article/view/3600
https://doi.org/10.52692/1857-0011.2023.3-77.39

Predicting the risk of developing drug-induced liver injury during remdesivir therapy in COVID-19 patients using machine learning ; Прогнозирование риска развития лекарственного поражения печени при терапии ремдесивиром у пациентов с COVID-19 с помощью машинного обучения

Authors: Yu. V. Shevchuk, I. I. Shamigulov, I. V. Sychev, A. V. Kryukov, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev, Ю. В. Шевчук, И. И. Шамигулов, И. В. Сычев, А. В. Крюков, И. И. Темирбулатов, К. Б. Мирзаев, Н. П. Денисенко, Ш. П. Абдуллаев, С. Н. Тучкова, В. И. Вечорко, О. В. Аверков, Д. А. Сычев

Contributors: Данная работа выполнена при финансовой поддержке Министерства здравоохранения Российской Федерации, тематика государственного задания «Разработка системы поддержки принятия врачебных решений для прогнозирования нежелательных лекарственных реакций у пациентов с COVID-19 на основе фармакогенетического тестирования» (ЕГИСУ НИОКТР № 122021800321-2).

Source: Acta Biomedica Scientifica; Том 9, № 6 (2024); 52-62 ; 2587-9596 ; 2541-9420

Subject Terms: модель риска, remdesivir, adverse drug reactions, hepatotoxicity, pharmacogenetic testing, predictors of adverse reactions, machine learning, risk model, ремдесивир, нежелательные реакции, гепатотоксичность, фармакогенетическое исследование, предикторы нежелательных реакций, машинное обучение

File Description: application/pdf

Relation: https://www.actabiomedica.ru/jour/article/view/5118/2933; Временные методические рекомендации по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19). М.; 2023.; Gilead Sciences Biopharmaceutical Companies, Veklury (remdesivir). U.S. Food and Drug Administration. 2022. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214787Orig1s010Lbl.pdf. [date of access: 20.05.2024].; Pantazis N, Pechlivanidou E, Antoniadou A, Akinosoglou K, Kalomenidis I, Poulakou G, et al. Remdesivir: Effectiveness and safety in hospitalized patients with COVID-19 (ReEs-COVID-19) – Analysis of data from daily practice. Microorganisms. 2023; 11(8): 1998. doi:10.3390/microorganisms11081998; Kang H, Kang CK, Im JH, Cho Y, Kang DY, Lee JY. Adverse drug events associated with remdesivir in real-world hospitalized patients with COVID-19, including vulnerable populations: A retrospective multicenter study. J Korean Med Sci. 2023; 38(44): e346. doi:10.3346/jkms.2023.38.e346; Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236): 1569-1578. doi:10.1016/S0140-6736(20)31022-9; Шевчук Ю.В., Крюков А.В., Темирбулатов И.И., Сычев И.В., Мирзаев К.Б., Денисенко Н.П., и др. Модель прогнозирования риска развития лекарственного поражения печени на фоне терапии ремдесивиром: обсервационное проспективное открытое контролируемое исследование. Фармация и фармакология. 2023; 11(3): 228-239. doi:10.19163/2307-9266-2023-11-3-228-239; Falconer N, Barras M, Cottrell N. Systematic review of predictive risk models for adverse drug events in hospitalized patients. Br J Clin Pharmacol. 2018; 84: 846-864. doi:10.1111/bcp.13514; Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, et al. The use of artificial intelligence in pharmacovigilance: A systematic review of the literature. Pharm Med. 2022; 36(5): 295-306. doi:10.1007/s40290-022-00441-z; Goldberger J, Roweis ST, Hinton GE, Salakhutdinov R. Neighbourhood components analysis. 2004: 513-520.; Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. 2013.; Cervantes J, Garcia-Lamont F, Rodríguez-Mazahua L, Lopez A. A comprehensive survey on support vector machine classification: Applications, challenges and trends. Neurocomputing. 2020; 408: 189-215. doi:10.1016/j.neucom.2019.10.118; Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. 2017. 13. Biau G, Scornet E. A random forest guided tour. TEST. 2016; 25(1): 197-227. doi:10.1007/s11749-016-0481-7; Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A. CatBoost: Unbiased boosting with categorical features. Advances in Neural Information Processing Systems. 2018; 31.; Hossin M, Sulaiman MN. A review on evaluation metrics for data classification evaluations. Int J Data Min Knowl Manag Process. 2015; 5(2): 1. doi:10.5121/ijdkp.2015.5201; O’Mahony D, O’Connor MN, Eustace J, Byrne S, Petrovic M, Gallagher P. The adverse drug reaction risk in older persons (ADRROP) prediction scale: Derivation and prospective validation of an ADR risk assessment tool in older multi-morbid patients. Eur Geriatr Med. 2018; 9(2): 191-199. doi:10.1007/s41999-018-0030-x; Lavan A, Eustace J, Dahly D, Flanagan E, Gallagher P, Cullinane S, et al. Incident adverse drug reactions in geriatric inpatients: A multicentred observational study. Ther Adv Drug Saf. 2018; 9(1): 13-23. doi:10.1177/2042098617736191; Yadesa TM, Kitutu FE, Tamukong R, Alele PE. Development and validation of ‘Prediction of Adverse Drug Reactions in Older Inpatients (PADROI)’ risk assessment tool. Clin Interv Aging. 2022; 17: 195-210. doi:10.2147/CIA.S350500; Zhang F, Sun B, Diao X, Zhao W, Shu T. Prediction of adverse drug reactions based on knowledge graph embedding. BMC Med Inform Decis Mak. 2021; 21: 1-11. doi:10.1186/s12911-021-01402-3; Galeano D, Li S, Gerstein M, Paccanaro A. Predicting the frequencies of drug side effects. Nat Commun. 2020; 11(1): 4575. doi:10.1038/s41467-020-18305-y; Choudhury O, Park Y, Salonidis T, Gkoulalas-Divanis A, Sylla I, Das AK. Predicting adverse drug reactions on distributed health data using federated learning. AMIA Annu Symp Proc. 2019; 2019: 313-322.; Ayyashi M, Darbashi H, Hakami A, Sharahili F. Evaluation of remdesivir utilization pattern in critically ill patients with COVID-19 in Jazan Province. Cureus. 2023; 15(3): e36247. doi:10.7759/cureus.36247; Iloanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: A systematic review. J Am Pharm Assoc. 2021; 61(5): e14-e25. doi:10.1016/j.japh.2021.05.006; Lee JY, Ang ASY, Mohd Ali N, Ang LM, Omar A. Incidence of adverse reaction of drugs used in COVID-19 management: A retrospective, observational study. J Pharm Policy Pract. 2021; 14: 1-9. doi:10.1186/s40545-021-00370-3; Sendekie AK, Kasahun AE, Limenh LW, Dagnaw AD, Belachew EA. Clinical and economic impact of adverse drug reactions in hospitalised patients: Prospective matched nested case-control study in Ethiopia. BMJ Open. 2023; 13: e073777. doi:10.1136/ bmjopen-2023-073777; Blair HA. Remdesivir: A review in COVID-19. Drugs. 2023; 83(13): 1215-1237. doi:10.1007/s40265-023-01926-0; Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. CYP3A4 and CYP3A5 genotyping recommendations: A joint consensus recommendation of the association for molecular pathology, clinical pharmacogenetics implementation consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2023; 25(9), 619-629. doi:10.1016/j.jmoldx.2023.06.008; Buscemi S, Corleo D, Randazzo C. Risk factors for COVID-19: Diabetes, hypertension, and obesity. Coronavirus Therapeutics, Volume II: Clinical Management and Public Health. 2022; 115-129. doi:10.1007/978-3-030-85113-2_7; Zhang X, Ha S, Lau HCH, Yu J. Excess body weight: Novel insights into its roles in obesity comorbidities. Semin Cancer Biol. 2023; 92: 16-27. doi:10.1016/j.semcancer.2023.03.008; Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023; 8(1): 20-30. doi:10.1016/S2468-1253(22)00317-X; https://www.actabiomedica.ru/jour/article/view/5118

Availability: https://www.actabiomedica.ru/jour/article/view/5118
https://doi.org/10.29413/ABS.2024-9.6.6

Profilul de siguranță al medicamentelor antituberculoase

Authors: Ţurcan, L.M., Podgurschi, L., Podgursky, L., Rakovskaia, T., Saitov, A.

Source: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 77 (3) 221-227

Subject Terms: противотуберкулезные препараты, hepatotoxicity, isoniazid, рифампицин, гепатотоксичность, изониазид, побочные эффекты, linezolid, rifampicin, preparate antituberculoase, side effects, isoniazida, neurotoxicity, reacții adverse medicamentoase, hepatotoxicitate, neurotoxicitate, rifampicină, antituberculosis drugs, линезолид, нейротоксичность

File Description: application/pdf

Access URL: https://ibn.idsi.md/vizualizare_articol/192709

EFFECT OF POWDER AND EXTRACTS OF FRUITS OF CARROT AND WILD CARROT ON THE BIOCHEMICAL COMPOSITION OF BLOOD AT LIVER TOXICITY

Authors: Svetlana Sergeevna Sigareva, Eugenia Aleksandrovna Vasilenko, Elena Olegovna Sergeeva

Source: Современная наука и инновации, Vol 0, Iss 1, Pp 135-139 (2022)

Subject Terms: порошок, экстракт, плоды моркови дикой, плоды моркови посевной, параце-тамоловая интоксикация, гепатотоксичность, powder, extract, fruits of wild carrot, fruits of carrot, paracetamol toxicity and hepatotoxicity, International relations, JZ2-6530

File Description: electronic resource

Relation: https://msi.elpub.ru/jour/article/view/872; https://doaj.org/toc/2307-910X

Access URL: https://doaj.org/article/e639adf3debd41d7830195ba5d1b9910

ИССЛЕДОВАНИЕ ХРОНИЧЕСКОЙ ГЕПАТОТОКСИЧНОСТИ НОВЫХ ПРОИЗВОДНЫХ КОНДЕНСИРОВАННЫХ 3-АМИНОТИЕНО[2,3-B]ПИРИДИНОВ И 1,4-ДИГИДРОПИРИДИНОВ С АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ

Subject Terms: hepatotoxicity, гепатотоксичность, 3-b]pyridines, 3. Good health, 3-b]пиридины, 4-дигидропиридины, condensed 3-aminothieno[2, анальгетическая активность, cyanothioacetamide derivatives, производные цианотиоцетамида, analgesic activity, 4-dihydropyridines, конденсированные 3-аминотиено[2

КОМПЕНДИУМ МЕТОДОЛОГИЧЕСКИХ ПОДХОДОВ ИНДУЦИРОВАНИЯ ГЕПАТОТОКСИЧНОСТИ У ЛАБОРАТОРНЫХ ЖИВОТНЫХ

Subject Terms: hepatotoxicity, гепатотоксичность, experiment, xenobiotics, печень, эксперимент, liver, ксенобиотики, 3. Good health

Терапевтическая эффективность S-аденозилметионина при хронической интоксикации ураном у крыс ; Therapeutic efficacy of S-adenosylmethionine in chronic uranium intoxication in rats

Authors: Sivak, K. V., Stosman, K. I., Savateeva-Lyubimova, T. N., Kalinina, E. Y., Rassokha, T. A., Сивак, К. В., Стосман, К. И., Саватеева-Любимова, Т. Н., Калинина, Е. Ю., Рассоха, Т. А.

Subject Terms: URANIUM COMPOUNDS, HEPATOTOXICITY, NEPHROTOXICITY, IMMUNOTOXICITY, S-ADENOSYLMETHIONINE, RATS, УРАНИЛ АЦЕТАТ ДИГИДРАТ, ГЕПАТОТОКСИЧНОСТЬ, НЕФРОТОКСИЧНОСТЬ, ИММУНОТОКСИЧНОСТЬ, S-АДЕНОЗИЛМЕТИОНИН, КРЫСЫ

File Description: application/pdf

Relation: Уральский медицинский журнал. 2023. Т. 22, № 6.; http://elib.usma.ru/handle/usma/18592

Availability: http://elib.usma.ru/handle/usma/18592

Antibiotic-Associated Drug-Induced Liver Injury in Critically Ill Children: A Prospective Observational Study ; Лекарственное поражение печени, ассоциированное с антибиотиками, у детей в критических состояниях: проспективное наблюдательное исследование

Authors: A. V. Vlasova, Yu. F. Shubina, D. A. Sychev, А. В. Власова, Ю. Ф. Шубина, Д. А. Сычев

Contributors: The study was performed without external funding, Работа выполнена без спонсорской поддержки

Source: Safety and Risk of Pharmacotherapy; Том 12, № 2 (2024); 155-166 ; Безопасность и риск фармакотерапии; Том 12, № 2 (2024); 155-166 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2024-12-2

Subject Terms: клиническое исследование, antibiotics, drug-induced liver diseases, DILI, hepatotoxicity, cholestatic hepatitis, adverse drug reactions, Global Trigger Tool, clinical trial, антибиотики, лекарственно-индуцированные заболевания печени, гепатотоксичность, холестатический гепатит, нежелательные реакции, метод глобальных триггеров

File Description: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/389/1152; https://www.risksafety.ru/jour/article/downloadSuppFile/389/379; Amin MD, Harpavat S, Leung DH. Drug-induced liver injury in children. Curr Opin Pediatr. 2015;27(5):625–33. https://doi.org/10.1097/mop.0000000000000264; Lee HH, Ho RH. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol. 2017;83(6):1176–84. https://doi.org/10.1111/bcp.13207; Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond). 2016;16(Suppl. 6):s104–s109. https://doi.org/10.7861/clinmedicine.16-6-s104; Anand AC, Nandi B, Acharya SK, Arora A, Babu S, Batra Y, et al. Indian national association for the study of the liver consensus statement on acute liver failure (Part 1): epidemiology, pathogenesis, presentation and prognosis. J Clin Exp Hepatol. 2020;10(4):339–76. https://doi.org/10.1016/j.jceh.2020.04.012; Donati M, Motola D. Leone R, Moretti U, Stoppa G, Arzenton E, et al. Liver injury due to amoxicillin vs. amoxicillin/clavulanate: a subgroup analysis of a drug-induced liver injury case-control study in Italy. J Hepatol Gastroint Dis. 2017;3(2):1–5. https://doi.org/10.4172/2475-3181.1000143; Teixeira M, Macedo S, Batista T, Martins S, Correia A, Costa Matos L. Flucloxacillin-induced hepatotoxicity-association with HLA-B*5701. Rev Assoc Med Bras (1992). 2020;66(1):12–7. https://doi.org/10.1590/1806-9282.66.1.12; Yu Y, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41. https://doi.org/10.1007/s12072-017-9793-2; Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21789 patients. Eur J Gastroenterol Hepatol. 2013;25(7):825–9. https://doi.org/10.1097/meg.0b013e32835f6889; Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5. https://doi.org/10.1053/jhep.2002.34857; Pinna AP, Locci G, Furno M, Fanni D, Faa G, Nurchi AM. DILI (drug-induced liver injury) in a 9-month-old infant: a rare case of phenobarbital-induced hepatotoxicity. J Pediatr Neonatal Individ Med JPNIM. 2013;2:93–5. https://doi.org/10.7363/020114; Sridharan K, Al Daylami A, Ajjawi R, Al Ajooz HA. Drug-induced liver injury in critically ill children taking antiepileptic drugs: a retrospective study. Curr Ther Res Clin Exp. 2020;92:100580. https://doi.org/10.1016/j.curtheres.2020.100580; Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21. https://doi.org/10.1016/j.gastro.2005.05.006; Chalasani N, Reddy K, Fontana R, Barnhart H, Gu J, Hayashi P, et al. Idiosyncratic drug-induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians. Am J Gastroenterol. 2017;112(9):1382–8. https://doi.org/10.1038/ajg.2017.215; Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 2017;37(2):173–8. https://doi.org/10.1111/liv.13308; deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, et al. Amoxicillin-clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406–16. https://doi.org/10.1007/s10620-016-4121-6; Iannelli V. 30 most commonly prescribed pediatric medications. 06.06.2023. https://www.verywellhealth.com/the-30-most-prescribed-drugs-in-pediatrics-2633435; Yamaguchi A, Tateishi T, Okano Y, Matuda T, Akimoto Y, Miyoshi T, et al. Higher incidence of elevated body temperature or increased C-reactive protein level in asthmatic children showing transient reduction of theophylline metabolism. J Clin Pharmacol. 2000;40(3):284–9. https://doi.org/10.1177/00912700022008955; Pokrajac M, Simić D, Varagić V. Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. Eur J Clin Pharmacol. 1987;33(5):483–6. https://doi.org/10.1007/bf00544240; Stephens M, Self T, Lancaster D, Nash T. Hypothyroidism: effect on warfarin anticoagulation. South Med J. 1989;82(12):1585–6. PMID: 2595433; Ersulo TA, Yizengaw MA, Tesfaye BT. Incidence of adverse drug events in patients hospitalized in the medical wards of a teaching referral hospital in Ethiopia: a prospective observational study. BMC Pharmacol Toxicol. 2022;23(1):30. https://doi.org/10.1186/s40360-022-00570-w; Kiguba R, Karamagi C, Bird SM. Incidence, risk factors and risk prediction of hospital-acquired suspected adverse drug reactions: a prospective cohort of Ugandan inpatients. BMJ Open. 2017;7(1):e010568. https://doi.org/10.1136/bmjopen-2015-010568; Zed PJ, Haughn C, Black KJL, Fitzpatrick EA, Ackroyd-Stolarz S, Murphy NG, et al. Medication-related emergency department visits and hospital admissions in pediatric patients: a qualitative systematic review. J Pediatr. 2013;163(2):477–83. https://doi.org/10.1016/j.jpeds.2013.01.042; Schumaker AL, Okulicz JF. Meropenem-induced vanishing bile duct syndrome. Pharmacotherapy. 2010;30(9):953. https://doi.org/10.1592/phco.30.9.953; Doß S, Blessing C, Haller K, Richter G, Sauer M. Influence of antibiotics on functionality and viability of liver cells in vitro. Curr Issues Mol Biol. 2022;44(10):4639–57. https://doi.org/10.3390/cimb44100317; Li L-M, Chen L, Deng G-H, Tan W-T, Dan Y-J, Wang R-Q, Chen W-S. SLCO1B1*15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep. 2012;6(1):75–82. https://doi.org/10.3892/mmr.2012.900; Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–64. https://doi.org/10.1016/j.cgh.2012.12.025; Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4(1):37–45. https://doi.org/10.1517/17425247.4.1.37; Buch S, Schafmayer C, Voelzke H, Seeger M, Miquel JF, Sookoian SC, et al. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology. 2010;139(6):1942–51. https://doi.org/10.1053/j.gastro.2010.09.003; Hoofnagle JH, Björnsson ES. Drug-induced liver injury — types and phenotypes. N Engl J Med. 2019;381(3):264–73. https://doi.org/10.1056/nejmra1816149; Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis. 2009;29(4):400–11. https://doi.org/10.1055/s-0029-1240009; Manolis E, Musuamba FT, Karlsson KE. The European Medicines Agency experience with pediatric dose selection. J Clin Pharmacol. 2021;61:S22–S27. https://doi.org/10.1002/jcph.1863; Власова АВ, Смирнова ЕВ, Горев ВВ, Сычев ДА. Нежелательные реакции детей на антимикробные препараты: ограничения метода спонтанных сообщений и возможности метода глобальных триггеров лекарственно-индуцированных состояний. Фарматека. 2023;30(1–2):18–31. https://doi.org/10.18565/pharmateca.2023.1-2.18-31; Classen DC, Resar R, Griffin F, Federico F, Frankel T, Kimmel N, et al. ‘Global Trigger Tool’ shows that adverse events in hospitals may be ten times greater than previously measured. Health Aff (Millwood). 2011;30(4):581–9. https://doi.org/10.1377/hlthaff.2011.0190; Иващенко ДВ, Буромская НИ, Савченко ЛМ, Шевченко ЮС, Сычев ДА. Значение метода глобальных триггеров для выявления неблагоприятных событий, связанных с оказанием медицинской помощи в педиатрии. Медицинский совет. 2018;(17):56–65. https://doi.org/10.21518/2079-701X-2018-17-56-65; Johnson AD, Kavousi M, Smith AV, Chen M-H, Dehghan A, Aspelund T, et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet. 2009;18(14):2700–10. https://doi.org/10.1093/hmg/ddp202; Yu Y, Nie X, Song Z, Xie Y, Zhang X, Du Z, et al. Signal detection of potentially drug-induced liver injury in children using electronic health records. Front Pediatr. 2020;8:171. https://doi.org/10.3389/fped.2020.00171; Jiang T, Huang X, Liu Q, Feng H, Huang Y, Lin J, et al. Risk factors for tigecycline-associated hepatotoxicity in patients in the intensive care units of 2 tertiary hospitals: a retrospective study. J Clin Pharmacol. 2022;62(11):1426–34. https://doi.org/10.1002/jcph.2099; Ghanem CI, Gómez PC, Arana MC, Perassolo M, Ruiz ML, Villanueva SS, et al. Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004;68(4):791–8. https://doi.org/10.1016/j.bcp.2004.05.014; Acevedo C, Bengochea L, Tchercansky DM, Ouviña G, Perazzo JC, Lago N, et al. Cholestasis as a liver protective factor in paracetamol acute overdose. Gen Pharmacol. 1995;26(7):1619–24. https://doi.org/10.1016/0306-3623(95)00061-5; https://www.risksafety.ru/jour/article/view/389

Availability: https://www.risksafety.ru/jour/article/view/389
https://doi.org/10.30895/2312-7821-2023-389

НАЗНАЧЕНИЕ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ СРЕДСТВ: ПОЛЬЗА И РИСКИ

Authors: Максим Станиславович Хорошун, Анастасия Андреевна Лазарева

Source: University Therapeutic Journal, Vol 4, Iss 1 (2022)

Subject Terms: нестероидные противовоспалительные препараты, нестероидная гастропатия, гепатотоксичность, нефротоксичность, поражения сердечно -сосудистой системы, Medicine

File Description: electronic resource

Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/4005; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920

Access URL: https://doaj.org/article/df0df1a8705c43cf88c24d9a6fa5511d

Поражение Печени При Коронавирусной Инфекции

Authors: Мехридинович, Нуриддинов Аслиддин

Source: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 1 No. 7 (2022): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 121-124 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 1 № 7 (2022): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 121-124 ; 2181-3469

Subject Terms: печень, коронавирусная инфекция, гепатотоксичность

File Description: application/pdf

Relation: https://sciencebox.uz/index.php/amaltibbiyot/article/view/4923/4441; https://sciencebox.uz/index.php/amaltibbiyot/article/view/4923

Availability: https://sciencebox.uz/index.php/amaltibbiyot/article/view/4923

Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors ; Вопросы безопасности терапии тоцилизумабом и другими ингибиторами интерлейкинов

Authors: V. I. Petrov, A. Y. Ryazanova, D. A. Nekrasov, V. I. Svinukhov, N. S. Privaltseva, В. И. Петров, А. Ю. Рязанова, Д. А. Некрасов, В. И. Свинухов, Н. С. Привальцева

Source: Safety and Risk of Pharmacotherapy; Том 10, № 1 (2022); 34-47 ; Безопасность и риск фармакотерапии; Том 10, № 1 (2022); 34-47 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2022-10-1

Subject Terms: межлекарственное взаимодействие, monoclonal antibodies, interleukins, interleukin receptors, tocilizumab, rheumatoid arthritis, COVID-19, adverse drug reactions, pharmacovigilance, hepatotoxity, drug-drug interactions, моноклональные антитела, интерлейкины, рецепторы интерлейкинов, тоцилизумаб, ревматоидный артрит, нежелательные реакции, фармаконадзор, гепатотоксичность

File Description: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/253/461; https://www.risksafety.ru/jour/article/downloadSuppFile/253/199; https://www.risksafety.ru/jour/article/downloadSuppFile/253/226; https://www.risksafety.ru/jour/article/downloadSuppFile/253/227; https://www.risksafety.ru/jour/article/downloadSuppFile/253/236; Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis. 2013;72(1):3–6. https://doi.org/10.1136/annrheumdis-2012-202361; Saki A, Rajaei E, Rahim F. Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and meta-analysis of clinical trial studies. Reumatologia. 2021;59(3):169–79. https://doi.org/10.5114/reum.2021.107026; Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141. https://doi.org/10.1186/ar3455; Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552–62. https://doi.org/10.1093/rheumatology/keq343; Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(6):905–10. https://doi.org/10.1136/annrheumdis-2017-212825; Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68(1):56–66. https://doi.org/10.1002/art.39399; Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford). 2017;56(10):1746–54. https://doi.org/10.1093/rheumatology/kex238; Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541–9. https://doi.org/10.1093/rheumatology/kew370; Choy E, Freemantle N, Proudfoot C, Chen C, Pollissard L, Kuznik A, et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019;5(1):e000798. https://doi.org/10.1136/rmdopen-2018-000798; Puxeddu I, Caltran E, Rocchi V, Del Corso I, Tavoni A, Migliorini P. Hypersensitivity reactions during treatment with biological agents. Clin Exp Rheumatol. 2016;34(1):129–32. PMID: 26751942; Pichler WJ. Adverse side effects to biological agents. Allergy. 2006;61(8):912–20. https://doi.org/10.1111/j.1398-9995.2006.01058.x; Yun H, Xie F, Beyl RN, Chen L, Lewis JD, Saag KG, Curtis JR. Risk of hypersensitivity to biologic agents among medicare patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2017;69(10):1526–34. https://doi.org/10.1002/acr.23141; Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, et al. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford). 2018;57(1):134–9. https://doi.org/10.1093/rheumatology/kex403; Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(8):1006–12. https://doi.org/10.1136/ard.2005.048371; Mahamid M, Mader R, Safadi R. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions. Clin Pharmacol. 2011;(3):39–43. https://doi.org/10.2147/cpaa.s24004; Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580–4. https://doi.org/10.1136/ard.2008.092866; Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, et al. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study. J Rheumatol. 2015;42(5):799–809. https://doi.org/10.3899/jrheum.140665; Jones G, Wallace T, McIntosh MJ, Brockwell L, Gomez-Reino J, Sebba A. Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate- and biologic-naive or free of methotrexate for 6 months: the AMBITION study. J Rheumatol. 2017;44(2):142–7. https://doi.org/10.3899/jrheum.160287; Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol. 2017;69(6):1154–64. https://doi.org/10.1002/art.40084; Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37(30):2406–13. https://doi.org/10.1093/eurheartj/ehw171; Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, Tomobe M, Totsuka K. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J Rheumatol. 2015 Aug;42(8):1368-75. doi:10.3899/jrheum.141210. Epub 2015 Jun 1. PMID: 26034149.; Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y, Sakai R, Yamazaki H, Koike T, Miyasaka N. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol. 2016 Sep;26(5):642-50. doi:10.3109/14397595.2016.1141740. Epub 2016 Mar 11. PMID: 26873430.; Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814–8. https://doi.org/10.1002/jmv.25801; Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–5. https://doi.org/10.1073/pnas.2005615117; Fomina DS, Lysenko MA, Beloglazova IP, Mutovana ZYu, Poteshkina NG, Samsonova IV, et al. Temporal clinical and laboratory response to interleukin-6 receptor blockade with tocilizumab in 89 hospitalized patients with COVID-19 pneumonia. Pathog Immun. 2020;5(1):327–41. https://doi.org/10.20411/pai.v5i1.392; RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45. https://doi.org/10.1016/s0140-6736(21)00676-0; Gundling S, Popa A, Tumbush C, Hejal RB, Giddings OK, Teba C, John AR. Safety of tocilizumab in patients with Covid-19. Am J Respir Crit Care Med. 2021;203:A3805. https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A3805; Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36–42. https://doi.org/10.1016/j.ejim.2020.05.011; Jiménez-Lozano I, Caro-Teller JM, Fernández-Hidalgo N, Miarons M, Frick MA, Batllori Badia E, et al. Safety of tocilizumab in COVID-19 pregnant women and their newborn: a retrospective study. J Clin Pharm Ther. 2021;46(4):1062–70. https://doi.org/10.1111/jcpt.13394; Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–9. https://doi.org/10.1016/j.ejim.2020.05.021; Rezaei S, Fatemi B, Karimi Majd Z, Minaei H, Peikanpour M, Anjidani N, et al. Efficacy and safety of tocilizumab in severe and critical COVID-19: a systematic review and meta-analysis. Expert Rev Clin Immunol. 2021;17(5):499–511. https://doi.org/10.1080/1744666x.2021.1908128; https://www.risksafety.ru/jour/article/view/253

Availability: https://www.risksafety.ru/jour/article/view/253
https://doi.org/10.30895/2312-7821-2022-10-1-34-47